Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_61f88efcda59d7062a4252ecf6886f58 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ec8277d9dd2f566d41ab3d1931b607ea |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4525 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2827 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2818 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04 |
filingDate |
2017-12-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ebe781ef969310161f5bab2934bd5120 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f5fab89dd5125cd6c1f1f2372945624f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e8117dc60e344031c2e6dc778586f444 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_df537b68a90eb58ee2217cf1e971a27a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f2dc9013ad7be8ca54c16c051d9ee16e |
publicationDate |
2019-11-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
BR-112019011627-A2 |
titleOfInvention |
oxabicycloheptanes for immune response modulation |
abstract |
The present invention relates to a method of treating a subject suffering from cancer comprising administering to the subject an effective amount of a pp2a inhibitor. |
priorityDate |
2016-12-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |